CD44 alternative splicing is a sensor of intragenic DNA methylation in tumors
Eric Batsch\'e, Oriane Mauger, Etienne Kornobis, Benjamin Hopkins,, Charlotte Hanmer-Lloyd, Christian Muchardt

TL;DR
This study reveals that intragenic DNA methylation influences alternative splicing of the CD44 gene in tumors, affecting tumor cell behavior and potentially serving as a biomarker for cancer progression.
Contribution
It demonstrates a direct link between DNA methylation and alternative splicing regulation in tumor cells, highlighting a novel epigenetic mechanism affecting tumorigenesis.
Findings
DNA methylation affects CD44 splicing in tumor cells
Altered methylation modifies recruitment of MBD1 and HP1γ
Splicing changes correlate with methylation levels in cancer samples
Abstract
DNA methylation (meDNA) is a suspected modulator of alternative splicing, while splicing in turn is involved in tumour formations nearly as frequently as DNA mutations. Yet, the impact of meDNA on tumorigenesis via its effect on splicing has not been thoroughly explored. Here, we find that HCT116 colon carcinoma cells inactivated for the DNA methylases DNMT1 and DNMT3b undergo a partial epithelial to mesenchymal transition (EMT) associated with alternative splicing of the CD44 transmembrane receptor. The skipping of CD44 variant exons is in part explained by altered expression or splicing of splicing and chromatin factors. A direct effect of meDNA on alternative splicing was sustained by transient depletion of DNMT1 and the methyl-binding genes MBD1, MBD2, and MBD3. Yet, local changes in intragenic meDNA also altered recruitment of MBD1 protein and of the chromatin factor HP1…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
